Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease - PubMed (original) (raw)
Review
. 2012 Nov;61(6):899-906.
doi: 10.1016/j.neuint.2012.01.031. Epub 2012 Feb 8.
Affiliations
- PMID: 22342821
- DOI: 10.1016/j.neuint.2012.01.031
Review
Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease
Steven P Braithwaite et al. Neurochem Int. 2012 Nov.
Abstract
Phosphorylation is a key post-translational modification for cellular signaling, and abnormalities in this process are observed in several neurodegenerative disorders. Among these disorders, Parkinson's disease (PD) is particularly intriguing as there are both genetic causes of disease that involve phosphorylation, and pathological hallmarks of disease composed of a hyperphosphorylated protein. Two of the major genes linked to PD are themselves kinases - leucine rich repeat kinase 2 (LRRK2) and phosphatase and tensin induced homolog kinase 1 (PINK1). Mutations in LRRK2 lead to its increased kinase activity and dominantly inherited PD, while mutations in PINK1 lead to loss of function and recessive PD. A third genetic linkage to disease is α-synuclein, a protein that is heavily phosphorylated in Lewy bodies and Lewy neurites, the pathological hallmarks of PD. The phosphorylation of α-synuclein at various residues influences its aggregation, either positively or negatively, thereby impacting its central role in disease pathogenesis. Given these associations of phosphorylation with PD, modulation of this modification is an attractive therapeutic strategy. The kinases that act in these disease relevant pathways have been the primary target for such approaches. But, the development of kinase inhibitors has been complicated by the necessary specificity to retain safety, the redundancy of kinases leading to lack of efficacy, and the difficulties in overcoming the blood-brain barrier. The field of modulating phosphatases has the potential to overcome some of these issues and provide the next generation of therapeutic targets for PD. In this review, we address the phosphorylation pathways involved in PD, the kinases and issues related to their inhibition, and the evolving field of the phosphatases relevant in PD and how they may be targeted pharmacologically.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
- α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP, Stock JB, Mouradian MM. Braithwaite SP, et al. Rev Neurosci. 2012 Mar 21;23(2):191-8. doi: 10.1515/revneuro-2011-0067. Rev Neurosci. 2012. PMID: 22499677 Review. - Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E, Baekelandt V, Taymans JM. Lobbestael E, et al. Biochem Soc Trans. 2012 Oct;40(5):1102-10. doi: 10.1042/BST20120128. Biochem Soc Trans. 2012. PMID: 22988873 Review. - Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR, Bakthavatchalam R. Kethiri RR, et al. Expert Opin Ther Pat. 2014 Jul;24(7):745-57. doi: 10.1517/13543776.2014.907275. Epub 2014 Jun 11. Expert Opin Ther Pat. 2014. PMID: 24918198 Review. - Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N, Chua G, Ranola M, Rowe DB, Halliday GM. Dzamko N, et al. J Parkinsons Dis. 2013;3(2):145-52. doi: 10.3233/JPD-130174. J Parkinsons Dis. 2013. PMID: 23938344 - Kinases as targets for Parkinson's disease: from genetics to therapy.
Vancraenenbroeck R, Lobbestael E, Maeyer MD, Baekelandt V, Taymans JM. Vancraenenbroeck R, et al. CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):724-40. doi: 10.2174/187152711797247858. CNS Neurol Disord Drug Targets. 2011. PMID: 21838679 Review.
Cited by
- Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.
Clark AR, Ohlmeyer M. Clark AR, et al. Pharmacol Ther. 2019 Sep;201:181-201. doi: 10.1016/j.pharmthera.2019.05.016. Epub 2019 Jun 1. Pharmacol Ther. 2019. PMID: 31158394 Free PMC article. Review. - PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation.
Iannotta L, Emanuele M, Favetta G, Tombesi G, Vandewynckel L, Lara Ordóñez AJ, Saliou JM, Drouyer M, Sibran W, Civiero L, Nichols RJ, Athanasopoulos PS, Kortholt A, Chartier-Harlin MC, Greggio E, Taymans JM. Iannotta L, et al. Front Mol Neurosci. 2023 Dec 18;16:1269387. doi: 10.3389/fnmol.2023.1269387. eCollection 2023. Front Mol Neurosci. 2023. PMID: 38169846 Free PMC article. - Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism.
Taymans JM, Baekelandt V. Taymans JM, et al. Front Genet. 2014 Nov 7;5:382. doi: 10.3389/fgene.2014.00382. eCollection 2014. Front Genet. 2014. PMID: 25426138 Free PMC article. Review. - Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Park HJ, Lee KW, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM. Park HJ, et al. J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110. J Neuropathol Exp Neurol. 2018. PMID: 29281045 Free PMC article. - Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.
Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM. Lee KW, et al. Neurotherapeutics. 2013 Jan;10(1):143-53. doi: 10.1007/s13311-012-0165-2. Neurotherapeutics. 2013. PMID: 23296837 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical